List view / Grid view

Enrique Conterno

 

news

BYDUREON™ receivies marketing authorisation in Europe

Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and…

21 June 2011 | By Eli Lilly and Company

Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced that the European Commission has granted marketing authorization to BYDUREON™...

news

FDA approves linagliptin tablets for the treatment of type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today…

3 May 2011 | By OgilvyHealthPR

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.1 The FDA has approved linagliptin as a monotherapy…